FTSE 100 pharma giants GSK and Astrazeneca appear to swerve Trump tariffs April 3, 2025 FTSE 100 pharma giants GSK and Astrazeneca may have escaped the worst of US President Donald Trump’s tariffs, according to a City broker. Pharmaceutical goods appear to be exempt from higher-rate tariffs introduced by President Trump in his Rose Garden ‘Liberation Day’ address on Wednesday, but there is still uncertainty about the impact on the [...]
Mark Kleinman: Football watchdog search approaches injury time March 6, 2025 Mark Kleinman is Sky News’ City Editor and the man who gets the Square Mile talking in his weekly City AM column. Today, he tackles the football watchdog search, big pay at GSK and CityFibre’s M&A warchest Football watchdog search approaches final whistle They think it’s all over. To paraphrase the immortal line of Kenneth Wolstenholme, the 1966 World [...]
FTSE 100 giant GSK eyes more than £40bn in sales by 2031 February 5, 2025 Pharmaceutical giant GSK has hiked its 2031 sales forecast to more than £40bn, up from £38bn, after reporting better than forecast fourth quarter earnings. The London-listed pharma giant reported core earnings per share of 23.2p for the quarter, a drop of around 20 per cent year-on-year. However, this was greater than the 19p that analysts [...]
GSK: Zantac settlements hit profit but guidance unchanged October 30, 2024 Pharmaceutical giant GSK has reported a drop in profit due to charges related to the Zantac lawsuits but has reaffirmed guidance and said its core outlook remained unchanged. Operating profit fell by 86 per cent, and earnings per share slumped due to a settlement charge of £1.8bn related to the Zantac lawsuits. The lawsuits arose [...]
GSK shares rise after £1.7bn Zantac settlement October 10, 2024 GSK shares have spiked today after the pharmaceutical giant agreed to pay as much as $2.2bn (£1.68bn) to settle lawsuits alleging one of its heartburn drugs had caused cancer. The discontinued version of the drug, Zantac, had triggered 80,000 lawsuits from 10 different law firms in the US and has hung over the FTSE 100 [...]
Pharma giants GSK, Pfizer and Sanofi granted supreme court hearing in Zantac cancer lawsuits August 28, 2024 Delaware’s top court is set to hear an appeal from GSK and other pharmaceutical giants to throw out over 70,000 lawsuits alleging that the now-discontinued heartburn drug Zantac caused cancer. The companies, which also include Pfizer and Sanofi, are challenging a lower court ruling that allowed expert testimony claiming Zantac causes cancer – a link [...]
GSK receives US breakthrough therapy designation for lung cancer treatment August 20, 2024 Pharmaceutical group GSK has been granted breakthrough therapy designation by the US Food and Drug Administration (FDA) for a key lung cancer treatment. The breakthrough therapy designation is designed to expedite the development and review of drugs with the potential to treat a serious condition. Only treatments that are shown to offer a substantial improvement [...]
GSK wins latest Zantac trial as jury finds drug did not cause woman’s cancer August 6, 2024 GSK - formerly GlaxoSmithKline - has won its latest trial over whether its most popular drug caused cancer on Monday, after a jury found it was not the root cause of an American woman's illness.
GSK: Pharma giant raises guidance after second quarter sales give shot in the arm July 31, 2024 London-listed pharma giant GSK has raised its guidance after a strong second quarter beat market expectations, boosted by its cancer and HIV portfolio. Total sales in the second quarter of 2024 reached £7.9bn, an increase of 13 per cent year on year. Core operating profit at the pharma company rose by 18 per cent on [...]
Consumer confidence hit highest level in three years July 19, 2024 Consumer confidence has risen to its highest level in three years in a tentative sign that the economy is leaving the cost-of-living crisis behind, new data from Deloitte shows. In its latest quarterly Consumer Tracker survey, Deloitte found that sentiment grew by 6.8 per cent year on year, boosted by a significant improvement in sentiment [...]